Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
22.29
-0.51 (-2.24%)
At close: Jul 20, 2026, 4:00 PM EDT
22.19
-0.10 (-0.47%)
After-hours: Jul 20, 2026, 7:34 PM EDT
Syndax Pharmaceuticals Revenue
Syndax Pharmaceuticals had revenue of $64.86M in the quarter ending March 31, 2026, with 223.64% growth. This brings the company's revenue in the last twelve months to $217.42M, up 397.28% year-over-year. In the year 2025, Syndax Pharmaceuticals had annual revenue of $172.35M with 627.84% growth.
Revenue (ttm)
$217.42M
Revenue Growth
+397.28%
P/S Ratio
9.09
Revenue / Employee
$728,772
Employees
298
Market Cap
1.98B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 172.35M | 148.67M | 627.84% |
| Dec 31, 2024 | 23.68M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 139.71M | 138.19M | 9,109.56% |
| Dec 31, 2020 | 1.52M | - | - |
| Dec 31, 2019 | 1.52M | - | - |
| Dec 31, 2018 | 1.52M | -591.00K | -28.04% |
| Dec 31, 2017 | 2.11M | 888.00K | 72.79% |
| Dec 31, 2016 | 1.22M | 593.00K | 94.58% |
| Dec 31, 2015 | 627.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.20B |
| ADMA Biologics | 509.86M |
| Aurinia Pharmaceuticals | 298.30M |
| Nuvation Bio | 143.05M |
| UroGen Pharma | 140.49M |
| AbCellera Biologics | 79.21M |
| Viridian Therapeutics | 70.92M |
| Ocular Therapeutix | 52.04M |
SNDX News
- 6 days ago - Syndax Pharmaceuticals Transcript: R&D Day 2026 - Transcripts
- 6 days ago - Syndax Pharmaceuticals Slides: FY 2026 - Filings
- 6 days ago - Syndax Pharmaceuticals Press release: FY 2026 - Filings
- 6 days ago - Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event - GlobeNewsWire
- 19 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Syndax price target lowered to $31 from $34 at Guggenheim - TheFly
- 5 weeks ago - Syndax presents data from SAVE trial at EHA - TheFly
- 5 weeks ago - Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 - GlobeNewsWire